Synlogic Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Synlogic han disminuido a una tasa media anual de -5.3%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 8.1% al año.

Información clave

-5.7%

Tasa de crecimiento de los beneficios

21.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	0.2%
Rentabilidad financiera	-549.5%
Margen neto	-2,284.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Sep 06

Synlogic's metabolic disorder drug gets FDA fast track status

Aug 23

Synlogic Q2 2022 Earnings Preview

Aug 10

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Aug 09

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Jul 12

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Jan 11

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Sep 28

Synlogic (SYBX) Investor Presentation - Slideshow

Jun 08

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Jun 03

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Feb 23

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

Jan 19

Synlogic outlines clinical milestones for 2021

Jan 11

Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary

Dec 15

Synlogic, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Synlogic EPS beats by $0.10

Nov 05

Desglose de ingresos y gastos

Cómo gana y gasta dinero Synlogic. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:SYBX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	3	-73	13	39
31 Dec 23	3	-57	15	44
30 Sep 23	1	-59	15	47
30 Jun 23	1	-65	16	52
31 Mar 23	1	-66	16	53
31 Dec 22	1	-66	17	52
30 Sep 22	2	-65	17	50
30 Jun 22	2	-63	16	49
31 Mar 22	2	-61	16	48
31 Dec 21	2	-61	15	47
30 Sep 21	1	-60	15	47
30 Jun 21	0	-57	14	44
31 Mar 21	0	-58	14	46
31 Dec 20	1	-59	14	47
30 Sep 20	2	-57	14	47
30 Jun 20	2	-57	15	47
31 Mar 20	2	-54	15	44
31 Dec 19	2	-51	15	42
30 Sep 19	1	-51	15	25
30 Jun 19	3	-48	15	24
31 Mar 19	3	-50	16	25
31 Dec 18	3	-48	16	23
30 Sep 18	3	-48	16	37
30 Jun 18	1	-49	16	36
31 Mar 18	3	-44	14	34
31 Dec 17	2	-40	13	30
30 Sep 17	2	-36	10	28
30 Jun 17	2	-29	9	23
31 Mar 17	0	-24	7	18
31 Dec 16	0	-21	6	15

Ingresos de calidad: SYBX actualmente no es rentable.

Margen de beneficios creciente: SYBX actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SYBX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 5.3% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SYBX en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: SYBX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: SYBX tiene una rentabilidad financiera negativa (-134.29%), ya que actualmente no es rentable.

Synlogic Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Price target decreased by 96% to US$1.00

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Consensus revenue estimates increase by 747%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$11.03 loss

New major risk - Revenue and earnings growth

Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?

Price target decreased by 11% to US$5.00

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Consensus revenue estimates increase by 11%, EPS downgraded

We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate

Consensus EPS estimates fall by 11%

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Consensus forecasts updated

Synlogic Therapeutics: SYNB1934 Advances To Phase 3

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Synlogic's metabolic disorder drug gets FDA fast track status

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Q2 2022 Earnings Preview

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Consensus forecasts updated

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$8.00

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Price target decreased to US$9.00

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Price target increased to US$10.00

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Consensus revenue estimates increase to US$389.7k

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic (SYBX) Investor Presentation - Slideshow

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Price target increased to US$10.00

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Synlogic Appoints Lisa Kelly-Croswell to Its Board of Directors

New 90-day high: US$4.90

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

New 90-day high: US$3.18

Synlogic outlines clinical milestones for 2021

Synlogic, Inc. Announces Advancement of SYNB1891

Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary